7 February 2024
Lovaltech is developing protein vaccines for nasal administration, giving them 3 major benefits:
- Stopping the transmission of viruses and therefore contagiousness,
- active on current but also future variants,
- and stable so they can be stored at room temperature.
In addition, Lovaltech vaccines are non-invasive, which presents an important advantage for the acceptance of vaccination, particularly among young people.
Find out more about Lovaltech: www.lovaltechnology.com